About OncoGenex

test

News

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014

Thursday, Mar 26 2015

OncoGenex to Report Financial Results for Fourth Quarter and Year End 2014 on March 26, 2015

Monday, Mar 23 2015

OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce™ Clinical Trial Evaluating Apatorsen in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Tuesday, Feb 24 2015

OncoGenex Announces Relocation of Corporate Headquarters, Expected to Yield Savings of at Least $4 Million Over Next Three Years

Thursday, Feb 12 2015

OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

Friday, Jan 16 2015

OncoGenex to Regain Rights to Custirsen from Teva

Tuesday, Dec 30 2014

OncoGenex Announces Results from the Phase 2 Borealis-1™ Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer

Friday, Dec 19 2014

Pages

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue